25 XP   0   0   10

GlaxoSmithKline Pharmaceuticals Limited
Buy, Hold or Sell?

Let's analyse GlaxoSmithKline Pharmaceuticals Limited together

PenkeI guess you are interested in GlaxoSmithKline Pharmaceuticals Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of GlaxoSmithKline Pharmaceuticals Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about GlaxoSmithKline Pharmaceuticals Limited

I send you an email if I find something interesting about GlaxoSmithKline Pharmaceuticals Limited.

Quick analysis of GlaxoSmithKline Pharmaceuticals Limited (30 sec.)










What can you expect buying and holding a share of GlaxoSmithKline Pharmaceuticals Limited? (30 sec.)

How much money do you get?

How much money do you get?
INR4.32
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
INR102.79
Expected worth in 1 year
INR-114.84
How sure are you?
90.0%

+ What do you gain per year?

Total Gains per Share
INR142.57
Return On Investment
7.2%

For what price can you sell your share?

Current Price per Share
INR1,972.30
Expected price per share
INR1,727 - INR2,524
How sure are you?
50%

1. Valuation of GlaxoSmithKline Pharmaceuticals Limited (5 min.)




Live pricePrice per Share (EOD)

INR1,972.30

Intrinsic Value Per Share

INR143.17 - INR490.01

Total Value Per Share

INR245.95 - INR592.79

2. Growth of GlaxoSmithKline Pharmaceuticals Limited (5 min.)




Is GlaxoSmithKline Pharmaceuticals Limited growing?

Current yearPrevious yearGrowGrow %
How rich?$208.9m$319.5m-$110.6m-52.9%

How much money is GlaxoSmithKline Pharmaceuticals Limited making?

Current yearPrevious yearGrowGrow %
Making money$73.2m$45.6m$27.5m37.6%
Net Profit Margin18.8%11.6%--

How much money comes from the company's main activities?

3. Financial Health of GlaxoSmithKline Pharmaceuticals Limited (5 min.)




What can you expect buying and holding a share of GlaxoSmithKline Pharmaceuticals Limited? (5 min.)

Welcome investor! GlaxoSmithKline Pharmaceuticals Limited's management wants to use your money to grow the business. In return you get a share of GlaxoSmithKline Pharmaceuticals Limited.

What can you expect buying and holding a share of GlaxoSmithKline Pharmaceuticals Limited?

First you should know what it really means to hold a share of GlaxoSmithKline Pharmaceuticals Limited. And how you can make/lose money.

Speculation

The Price per Share of GlaxoSmithKline Pharmaceuticals Limited is INR1,972. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of GlaxoSmithKline Pharmaceuticals Limited.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in GlaxoSmithKline Pharmaceuticals Limited, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is INR102.79. Based on the TTM, the Book Value Change Per Share is INR-54.41 per quarter. Based on the YOY, the Book Value Change Per Share is INR68.70 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is INR90.05 per quarter.
Based on historical numbers we can estimate the returns while holding a share of GlaxoSmithKline Pharmaceuticals Limited.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 INR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per Share
Usd Eps0.430.0%0.430.0%1.200.1%0.450.0%0.360.0%
Usd Book Value Change Per Share-0.650.0%-0.650.0%0.820.0%-0.040.0%-0.020.0%
Usd Dividend Per Share1.080.1%1.080.1%0.360.0%0.470.0%0.380.0%
Usd Total Gains Per Share0.430.0%0.430.0%1.180.1%0.430.0%0.360.0%
Usd Price Per Share15.90-15.90-20.00-16.77-17.17-
Price to Earnings Ratio36.75-36.75-16.66-79.89-72.62-
Price-to-Total Gains Ratio37.17-37.17-16.90-253.62-130.05-
Price to Book Ratio12.89-12.89-10.60-12.35-12.38-
Price-to-Total Gains Ratio37.17-37.17-16.90-253.62-130.05-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share23.6676
Number of shares42
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share1.080.47
Usd Book Value Change Per Share-0.65-0.04
Usd Total Gains Per Share0.430.43
Gains per Quarter (42 shares)17.9618.02
Gains per Year (42 shares)71.8672.09
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1182-1106280-862
2363-219134159-15134
3545-329206239-23206
4726-439278318-30278
5908-548350398-38350
61089-658422478-45422
71271-768494557-53494
81452-877566637-60566
91634-987638717-68638
101815-1097710796-75710

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%19.00.00.0100.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%5.05.00.050.0%13.06.00.068.4%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%19.00.00.0100.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%9.01.00.090.0%18.01.00.094.7%

Fundamentals of GlaxoSmithKline Pharmaceuticals Limited

About GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of Shingles and Post herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, which are antibiotics to treat bacterial infections; CALPOL for treatment of mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment and prevention of specific bacterial skin infections; BETNOVATE for skin conditions which require relief of inflammation; T-BACT for bacterial skin infections; TENOVATE and Flutivate for skin conditions to reduce inflammation; PHYSIOGEL for dry skin and dry skin associated with redness and itch; Zimig for fungal skin infections; COBADEX CZS, a multivitamin; and Supacef, a bactericidal cephalosporin antibiotic. Further, it develops products for infectious diseases, HIV, oncology, and immunology. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.

Fundamental data was last updated by Penke on 2024-04-21 20:00:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is very efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very efficient.
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is overpriced.

1.1. Profitability of GlaxoSmithKline Pharmaceuticals Limited.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit GlaxoSmithKline Pharmaceuticals Limited earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compare GlaxoSmithKline Pharmaceuticals Limited to the Drug Manufacturers - General industry mean.
  • A Net Profit Margin of 18.8% means that ₹0.19 for each ₹1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 18.8%. The company is making a huge profit. +2
  • The TTM is 18.8%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ18.8%TTM18.8%0.0%
TTM18.8%YOY11.6%+7.2%
TTM18.8%5Y11.7%+7.0%
5Y11.7%10Y12.9%-1.2%
1.1.2. Return on Assets

Shows how efficient GlaxoSmithKline Pharmaceuticals Limited is using its assets to generate profit.

  • Above 5% is considered healthy but always compare GlaxoSmithKline Pharmaceuticals Limited to the Drug Manufacturers - General industry mean.
  • 18.4% Return on Assets means that GlaxoSmithKline Pharmaceuticals Limited generated ₹0.18 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 18.4%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 18.4%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ18.4%TTM18.4%0.0%
TTM18.4%YOY8.2%+10.1%
TTM18.4%5Y10.5%+7.9%
5Y10.5%10Y11.2%-0.7%
1.1.3. Return on Equity

Shows how efficient GlaxoSmithKline Pharmaceuticals Limited is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare GlaxoSmithKline Pharmaceuticals Limited to the Drug Manufacturers - General industry mean.
  • 35.1% Return on Equity means GlaxoSmithKline Pharmaceuticals Limited generated ₹0.35 for each ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 35.1%. Using its investors money, the company is very efficient in making profit. +2
  • The TTM is 35.1%. Using its investors money, the company is very efficient in making profit. +2
Trends
Current periodCompared to+/- 
MRQ35.1%TTM35.1%0.0%
TTM35.1%YOY14.3%+20.8%
TTM35.1%5Y19.8%+15.2%
5Y19.8%10Y19.5%+0.3%

1.2. Operating Efficiency of GlaxoSmithKline Pharmaceuticals Limited.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient GlaxoSmithKline Pharmaceuticals Limited is operating .

  • Measures how much profit GlaxoSmithKline Pharmaceuticals Limited makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare GlaxoSmithKline Pharmaceuticals Limited to the Drug Manufacturers - General industry mean.
  • An Operating Margin of 25.8% means the company generated ₹0.26  for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 25.8%. The company is operating very efficient. +2
  • The TTM is 25.8%. The company is operating very efficient. +2
Trends
Current periodCompared to+/- 
MRQ25.8%TTM25.8%0.0%
TTM25.8%YOY23.5%+2.3%
TTM25.8%5Y22.2%+3.6%
5Y22.2%10Y21.5%+0.7%
1.2.2. Operating Ratio

Measures how efficient GlaxoSmithKline Pharmaceuticals Limited is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • An Operation Ratio of 0.77 means that the operating costs are ₹0.77 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 0.773. The company is efficient in keeping operating costs low. +1
  • The TTM is 0.773. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ0.773TTM0.7730.000
TTM0.773YOY0.787-0.014
TTM0.7735Y0.806-0.033
5Y0.80610Y0.864-0.058

1.3. Liquidity of GlaxoSmithKline Pharmaceuticals Limited.

1.3. Liquidity
1.3.1. Current Ratio

Measures if GlaxoSmithKline Pharmaceuticals Limited is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A Current Ratio of 1.88 means the company has ₹1.88 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 1.881. The company is able to pay all its short-term debts. +1
  • The TTM is 1.881. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.881TTM1.8810.000
TTM1.881YOY2.183-0.303
TTM1.8815Y1.766+0.115
5Y1.76610Y2.267-0.501
1.3.2. Quick Ratio

Measures if GlaxoSmithKline Pharmaceuticals Limited is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare GlaxoSmithKline Pharmaceuticals Limited to the Drug Manufacturers - General industry mean.
  • A Quick Ratio of 2.85 means the company can pay off ₹2.85 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 2.851. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.851. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.851TTM2.8510.000
TTM2.851YOY3.407-0.556
TTM2.8515Y2.378+0.473
5Y2.37810Y2.915-0.537

1.4. Solvency of GlaxoSmithKline Pharmaceuticals Limited.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of GlaxoSmithKline Pharmaceuticals Limited assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare GlaxoSmithKline Pharmaceuticals Limited to Drug Manufacturers - General industry mean.
  • A Debt to Asset Ratio of 0.48 means that GlaxoSmithKline Pharmaceuticals Limited assets are financed with 47.7% credit (debt) and the remaining percentage (100% - 47.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 0.477. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.477. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.477TTM0.4770.000
TTM0.477YOY0.425+0.051
TTM0.4775Y0.459+0.018
5Y0.45910Y0.415+0.043
1.4.2. Debt to Equity Ratio

Measures if GlaxoSmithKline Pharmaceuticals Limited is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare GlaxoSmithKline Pharmaceuticals Limited to the Drug Manufacturers - General industry mean.
  • A Debt to Equity ratio of 91.0% means that company has ₹0.91 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 0.910. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.910. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.910TTM0.9100.000
TTM0.910YOY0.740+0.171
TTM0.9105Y0.855+0.055
5Y0.85510Y0.738+0.117

2. Market Valuation of GlaxoSmithKline Pharmaceuticals Limited

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₹1 in earnings GlaxoSmithKline Pharmaceuticals Limited generates.

  • Above 15 is considered overpriced but always compare GlaxoSmithKline Pharmaceuticals Limited to the Drug Manufacturers - General industry mean.
  • A PE ratio of 36.75 means the investor is paying ₹36.75 for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The EOD is 54.712. Based on the earnings, the company is expensive. -2
  • The MRQ is 36.749. Based on the earnings, the company is overpriced. -1
  • The TTM is 36.749. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD54.712MRQ36.749+17.963
MRQ36.749TTM36.7490.000
TTM36.749YOY16.663+20.086
TTM36.7495Y79.890-43.141
5Y79.89010Y72.618+7.272
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The EOD is 75.903. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The MRQ is 50.983. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The TTM is 50.983. Based on how much money comes from the company's main activities, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD75.903MRQ50.983+24.921
MRQ50.983TTM50.9830.000
TTM50.983YOY36.385+14.598
TTM50.9835Y80.019-29.036
5Y80.01910Y27.372+52.647
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of GlaxoSmithKline Pharmaceuticals Limited is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A PB ratio of 12.89 means the investor is paying ₹12.89 for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The EOD is 19.188. Based on the equity, the company is expensive. -2
  • The MRQ is 12.888. Based on the equity, the company is expensive. -2
  • The TTM is 12.888. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD19.188MRQ12.888+6.300
MRQ12.888TTM12.8880.000
TTM12.888YOY10.604+2.284
TTM12.8885Y12.349+0.539
5Y12.34910Y12.380-0.031
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of GlaxoSmithKline Pharmaceuticals Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---54.406-54.4060%68.703-179%-3.731-93%-1.568-97%
Book Value Per Share--102.787102.7870%157.194-35%116.451-12%118.401-13%
Current Ratio--1.8811.8810%2.183-14%1.766+6%2.267-17%
Debt To Asset Ratio--0.4770.4770%0.425+12%0.459+4%0.415+15%
Debt To Equity Ratio--0.9100.9100%0.740+23%0.855+6%0.738+23%
Dividend Per Share--90.05090.0500%29.907+201%39.491+128%31.358+187%
Eps--36.04936.0490%100.039-64%37.804-5%30.274+19%
Free Cash Flow Per Share--25.98425.9840%45.813-43%25.887+0%14.541+79%
Free Cash Flow To Equity Per Share---65.118-65.1180%14.868-538%-16.021-75%-20.270-69%
Gross Profit Margin--0.7280.7280%0.517+41%0.229+218%0.425+71%
Intrinsic Value_10Y_max--490.006--------
Intrinsic Value_10Y_min--143.168--------
Intrinsic Value_1Y_max--37.681--------
Intrinsic Value_1Y_min--14.640--------
Intrinsic Value_3Y_max--121.920--------
Intrinsic Value_3Y_min--43.994--------
Intrinsic Value_5Y_max--216.654--------
Intrinsic Value_5Y_min--73.129--------
Market Cap334119453800.000+33%224420643541.500224420643541.5000%282382918074.600-21%236736462213.300-5%242423586357.126-7%
Net Profit Margin--0.1880.1880%0.116+62%0.117+60%0.129+45%
Operating Margin--0.2580.2580%0.235+10%0.222+16%0.215+20%
Operating Ratio--0.7730.7730%0.787-2%0.806-4%0.864-11%
Pb Ratio19.188+33%12.88812.8880%10.604+22%12.349+4%12.380+4%
Pe Ratio54.712+33%36.74936.7490%16.663+121%79.890-54%72.618-49%
Price Per Share1972.300+33%1324.7501324.7500%1666.900-21%1397.450-5%1431.021-7%
Price To Free Cash Flow Ratio75.903+33%50.98350.9830%36.385+40%80.019-36%27.372+86%
Price To Total Gains Ratio55.334+33%37.16737.1670%16.904+120%253.616-85%130.049-71%
Quick Ratio--2.8512.8510%3.407-16%2.378+20%2.915-2%
Return On Assets--0.1840.1840%0.082+123%0.105+75%0.112+64%
Return On Equity--0.3510.3510%0.143+145%0.198+77%0.195+80%
Total Gains Per Share--35.64435.6440%98.610-64%35.7600%29.790+20%
Usd Book Value--208953600.000208953600.0000%319554696.000-35%236729990.400-12%240693808.800-13%
Usd Book Value Change Per Share---0.653-0.6530%0.824-179%-0.045-93%-0.019-97%
Usd Book Value Per Share--1.2331.2330%1.886-35%1.397-12%1.421-13%
Usd Dividend Per Share--1.0811.0810%0.359+201%0.474+128%0.376+187%
Usd Eps--0.4330.4330%1.200-64%0.454-5%0.363+19%
Usd Free Cash Flow--52822800.00052822800.0000%93132816.000-43%52624653.600+0%29559036.960+79%
Usd Free Cash Flow Per Share--0.3120.3120%0.550-43%0.311+0%0.174+79%
Usd Free Cash Flow To Equity Per Share---0.781-0.7810%0.178-538%-0.192-75%-0.243-69%
Usd Market Cap4009433445.600+33%2693047722.4982693047722.4980%3388595016.895-21%2840837546.560-5%2909083036.286-7%
Usd Price Per Share23.668+33%15.89715.8970%20.003-21%16.769-5%17.172-7%
Usd Profit--73282416.00073282416.0000%45692268.000+60%45316814.400+62%45784317.840+60%
Usd Revenue--390206400.000390206400.0000%393363504.000-1%385946661.600+1%357812622.000+9%
Usd Total Gains Per Share--0.4280.4280%1.183-64%0.4290%0.357+20%
 EOD+4 -4MRQTTM+0 -0YOY+11 -255Y+18 -1810Y+19 -17

3.2. Fundamental Score

Let's check the fundamental score of GlaxoSmithKline Pharmaceuticals Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1554.712
Price to Book Ratio (EOD)Between0-119.188
Net Profit Margin (MRQ)Greater than00.188
Operating Margin (MRQ)Greater than00.258
Quick Ratio (MRQ)Greater than12.851
Current Ratio (MRQ)Greater than11.881
Debt to Asset Ratio (MRQ)Less than10.477
Debt to Equity Ratio (MRQ)Less than10.910
Return on Equity (MRQ)Greater than0.150.351
Return on Assets (MRQ)Greater than0.050.184
Total8/10 (80.0%)

3.3. Technical Score

Let's check the technical score of GlaxoSmithKline Pharmaceuticals Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.693
Ma 20Greater thanMa 501,992.870
Ma 50Greater thanMa 1002,011.666
Ma 100Greater thanMa 2002,067.980
OpenGreater thanClose1,975.950
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-03-312020-03-312021-03-312022-03-312023-03-31
Net Interest Income  767,249-68,549698,700-21,100677,600-429,200248,400-266,500-18,100



Latest Balance Sheet

Balance Sheet of 2023-03-31. Currency in INR. All numbers in thousands.

Summary
Total Assets33,265,800
Total Liabilities15,853,000
Total Stockholder Equity17,412,800
 As reported
Total Liabilities 15,853,000
Total Stockholder Equity+ 17,412,800
Total Assets = 33,265,800

Assets

Total Assets33,265,800
Total Current Assets24,942,600
Long-term Assets8,323,200
Total Current Assets
Cash And Cash Equivalents 349,400
Short-term Investments 17,769,300
Net Receivables 1,923,800
Inventory 4,599,700
Other Current Assets 300,400
Total Current Assets  (as reported)24,942,600
Total Current Assets  (calculated)24,942,600
+/-0
Long-term Assets
Property Plant Equipment 3,151,200
Goodwill -8
Intangible Assets 340,908
Long-term Assets  (as reported)8,323,200
Long-term Assets  (calculated)3,492,100
+/- 4,831,100

Liabilities & Shareholders' Equity

Total Current Liabilities13,263,600
Long-term Liabilities2,589,400
Total Stockholder Equity17,412,800
Total Current Liabilities
Short-term Debt 120,800
Accounts payable 4,277,900
Other Current Liabilities 562,000
Total Current Liabilities  (as reported)13,263,600
Total Current Liabilities  (calculated)4,960,700
+/- 8,302,900
Long-term Liabilities
Capital Lease Obligations 155,400
Long-term Liabilities  (as reported)2,589,400
Long-term Liabilities  (calculated)155,400
+/- 2,434,000
Total Stockholder Equity
Common Stock1,694,100
Retained Earnings 8,114,914
Accumulated Other Comprehensive Income 7,432,935
Other Stockholders Equity 170,851
Total Stockholder Equity (as reported)17,412,800
Total Stockholder Equity (calculated)17,412,800
+/-0
Other
Capital Stock1,694,100
Cash and Short Term Investments 18,118,700
Common Stock Shares Outstanding 169,406
Current Deferred Revenue8,302,900
Liabilities and Stockholders Equity 33,265,800
Net Debt -194,000
Net Invested Capital 17,412,800
Net Working Capital 11,679,000
Property Plant and Equipment Gross 3,151,200
Short Long Term Debt Total 155,400



Balance Sheet

Currency in INR. All numbers in thousands.

 Trend2023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-312016-03-312015-03-312014-03-312013-03-312012-03-312011-03-312010-03-312009-03-312008-03-312007-03-312006-03-312005-03-31
> Total Assets 
14,139,981
15,159,355
17,890,900
20,360,989
23,205,280
24,977,979
28,104,738
30,657,733
30,883,991
31,295,235
32,244,246
30,460,135
30,038,353
39,474,827
39,113,109
31,355,410
31,133,608
46,332,778
33,265,800
33,265,80046,332,77831,133,60831,355,41039,113,10939,474,82730,038,35330,460,13532,244,24631,295,23530,883,99130,657,73328,104,73824,977,97923,205,28020,360,98917,890,90015,159,35514,139,981
   > Total Current Assets 
5,004,567
4,685,706
5,189,358
5,665,627
14,517,475
21,826,812
25,095,695
27,614,235
26,466,705
26,239,371
25,743,979
21,720,992
16,726,164
21,814,708
20,061,349
17,748,814
22,026,543
37,080,323
24,942,600
24,942,60037,080,32322,026,54317,748,81420,061,34921,814,70816,726,16421,720,99225,743,97926,239,37126,466,70527,614,23525,095,69521,826,81214,517,4755,665,6275,189,3584,685,7065,004,567
       Cash And Cash Equivalents 
715,322
475,968
358,186
1,549,947
9,567,349
17,339,019
20,028,950
20,430,595
20,490,145
20,220,758
1,153,021
13,226,626
1,409,229
12,701,163
987,766
1,048,115
4,051,892
2,861,871
349,400
349,4002,861,8714,051,8921,048,115987,76612,701,1631,409,22913,226,6261,153,02120,220,75820,490,14520,430,59520,028,95017,339,0199,567,3491,549,947358,186475,968715,322
       Short-term Investments 
0
0
0
0
0
0
0
0
0
100,025
18,399,238
12,520,609
7,672,460
10,690,145
10,490,145
9,570,145
7,320,145
26,165,395
17,769,300
17,769,30026,165,3957,320,1459,570,14510,490,14510,690,1457,672,46012,520,60918,399,238100,025000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
1,518,265
1,658,545
1,816,938
2,577,483
2,042,242
2,100,075
2,238,757
5,130,296
2,665,767
1,923,800
1,923,8002,665,7675,130,2962,238,7572,100,0752,042,2422,577,4831,816,9381,658,5451,518,265000000000
       Inventory 
2,303,934
2,223,173
2,467,854
2,112,069
2,329,760
2,572,972
2,855,541
3,334,369
2,851,451
3,469,700
3,755,827
5,258,666
4,257,974
5,001,833
4,864,935
4,830,322
5,466,981
5,346,954
4,599,700
4,599,7005,346,9545,466,9814,830,3224,864,9355,001,8334,257,9745,258,6663,755,8273,469,7002,851,4513,334,3692,855,5412,572,9722,329,7602,112,0692,467,8542,223,1732,303,934
       Other Current Assets 
1,985,311
1,986,565
2,363,318
2,003,611
2,620,366
1,914,821
2,211,204
3,849,271
3,125,109
2,548,913
2,435,893
3,235,700
3,386,501
58,576
83,247
61,475
57,229
40,336
300,400
300,40040,33657,22961,47583,24758,5763,386,5013,235,7002,435,8932,548,9133,125,1093,849,2712,211,2041,914,8212,620,3662,003,6112,363,3181,986,5651,985,311
   > Long-term Assets 
9,135,414
10,473,649
12,701,542
14,695,362
8,687,805
3,151,167
3,009,043
3,043,498
4,417,286
5,055,864
6,500,267
8,739,143
13,312,189
17,660,119
19,051,760
13,606,596
9,107,065
9,252,247
8,323,200
8,323,2009,252,2479,107,06513,606,59619,051,76017,660,11913,312,1898,739,1436,500,2675,055,8644,417,2863,043,4983,009,0433,151,1678,687,80514,695,36212,701,54210,473,6499,135,414
       Property Plant Equipment 
842,613
914,003
946,445
507,835
582,236
1,141,860
1,176,748
824,116
1,332,104
1,619,527
2,382,840
4,717,324
8,259,263
11,730,238
13,670,968
8,270,867
3,541,241
3,254,472
3,151,200
3,151,2003,254,4723,541,2418,270,86713,670,96811,730,2388,259,2634,717,3242,382,8401,619,5271,332,104824,1161,176,7481,141,860582,236507,835946,445914,003842,613
       Goodwill 
126,452
84,303
42,154
421,497
421,497
0
0
421,497
0
0
0
0
0
0
0
0
0
0
-8
-80000000000421,49700421,497421,49742,15484,303126,452
       Long Term Investments 
0
0
0
0
0
0
0
0
0
550
695
550
550
550
550
0
0
0
0
0000550550550550695550000000000
       Intangible Assets 
74,517
57,341
0
0
0
0
0
0
0
0
0
0
322,473
726,818
655,400
496,251
433,640
344,974
340,908
340,908344,974433,640496,251655,400726,818322,473000000000057,34174,517
       Long-term Assets Other 
7,492,118
9,004,437
11,359,241
13,464,623
7,295,182
1,484,589
1,179,002
1,121,899
2,217,969
2,513,444
21,564,364
3,133,929
11,486,082
4,165,821
4,103,177
30,326
11,380,968
30,768,320
21,143,800
21,143,80030,768,32011,380,96830,3264,103,1774,165,82111,486,0823,133,92921,564,3642,513,4442,217,9691,121,8991,179,0021,484,5897,295,18213,464,62311,359,2419,004,4377,492,118
> Total Liabilities 
4,902,492
5,627,818
5,843,448
6,552,608
7,449,979
7,117,042
8,588,929
11,300,749
10,815,678
11,397,885
7,803,463
13,499,437
9,969,795
18,901,538
17,714,817
13,149,361
16,142,811
19,703,220
15,853,000
15,853,00019,703,22016,142,81113,149,36117,714,81718,901,5389,969,79513,499,4377,803,46311,397,88510,815,67811,300,7498,588,9297,117,0427,449,9796,552,6085,843,4485,627,8184,902,492
   > Total Current Liabilities 
4,712,553
5,464,819
5,681,974
6,396,469
7,302,408
6,986,987
8,449,910
11,192,099
8,363,985
8,889,091
5,002,062
10,575,175
7,202,325
15,998,637
14,543,195
10,242,572
13,324,743
16,984,288
13,263,600
13,263,60016,984,28813,324,74310,242,57214,543,19515,998,6377,202,32510,575,1755,002,0628,889,0918,363,98511,192,0998,449,9106,986,9877,302,4086,396,4695,681,9745,464,8194,712,553
       Short-term Debt 
627
601
410
270
237
132
0
0
4,509
5,374
4,895
7,780
6,060
4,060
4,060
149,788
143,767
124,530
120,800
120,800124,530143,767149,7884,0604,0606,0607,7804,8955,3744,50900132237270410601627
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
41,424
4,895
7,780
6,060
4,060
4,060
1,530
240
0
0
002401,5304,0604,0606,0607,7804,89541,424000000000
       Accounts payable 
2,056,992
2,397,075
2,325,495
2,283,263
2,550,808
2,944,239
3,343,562
3,424,516
2,392,184
2,895,158
3,080,390
4,002,284
2,789,273
5,058,552
4,058,148
3,575,851
4,644,700
5,705,487
4,277,900
4,277,9005,705,4874,644,7003,575,8514,058,1485,058,5522,789,2734,002,2843,080,3902,895,1582,392,1843,424,5163,343,5622,944,2392,550,8082,283,2632,325,4952,397,0752,056,992
       Other Current Liabilities 
2,654,934
3,067,143
3,356,069
4,112,936
4,751,363
4,042,616
5,106,348
7,767,583
5,967,292
5,988,559
1,720,333
6,565,111
4,385,884
10,936,025
10,480,987
170,000
170,000
11,110,797
562,000
562,00011,110,797170,000170,00010,480,98710,936,0254,385,8846,565,1111,720,3335,988,5595,967,2927,767,5835,106,3484,042,6164,751,3634,112,9363,356,0693,067,1432,654,934
   > Long-term Liabilities 
189,939
162,999
161,474
156,139
147,571
130,055
139,019
108,650
2,451,693
2,508,794
2,801,401
2,924,262
2,767,470
2,902,901
3,171,622
2,906,789
2,818,068
2,718,932
2,589,400
2,589,4002,718,9322,818,0682,906,7893,171,6222,902,9012,767,4702,924,2622,801,4012,508,7942,451,693108,650139,019130,055147,571156,139161,474162,999189,939
       Other Liabilities 
0
0
0
0
0
0
0
0
0
2,472,744
2,775,141
2,908,312
2,757,580
2,897,071
3,169,852
2,638,177
2,615,569
2,642,697
0
02,642,6972,615,5692,638,1773,169,8522,897,0712,757,5802,908,3122,775,1412,472,744000000000
> Total Stockholder Equity
9,237,489
9,531,537
12,047,452
13,808,381
15,755,301
17,860,937
19,515,809
19,356,984
20,068,313
19,897,350
24,440,783
16,960,698
20,068,558
20,573,289
21,398,292
18,206,049
14,990,797
26,629,558
17,412,800
17,412,80026,629,55814,990,79718,206,04921,398,29220,573,28920,068,55816,960,69824,440,78319,897,35020,068,31319,356,98419,515,80917,860,93715,755,30113,808,38112,047,4529,531,5379,237,489
   Common Stock
873,225
847,030
847,030
847,030
847,030
847,030
847,030
847,030
847,030
847,030
847,030
847,030
847,030
847,030
1,694,060
1,694,060
1,694,060
1,694,060
1,694,100
1,694,1001,694,0601,694,0601,694,0601,694,060847,030847,030847,030847,030847,030847,030847,030847,030847,030847,030847,030847,030847,030873,225
   Retained Earnings Total Equity0000000000000000000
   Accumulated Other Comprehensive Income 
-1,577,049
-1,618,977
-1,696,366
-2,233,575
-2,358,700
-1,983,426
-2,114,389
-2,166,506
-1,846,066
-2,009,815
0
-1,884,636
-463,763
-791,922
-1,154,161
7,756,808
7,528,126
7,510,073
7,432,935
7,432,9357,510,0737,528,1267,756,808-1,154,161-791,922-463,763-1,884,6360-2,009,815-1,846,066-2,166,506-2,114,389-1,983,426-2,358,700-2,233,575-1,696,366-1,618,977-1,577,049
   Capital Surplus 0000000000000000000
   Treasury Stock0000000000000000000
   Other Stockholders Equity 
9,941,313
10,303,484
12,896,788
15,194,926
17,266,971
18,997,333
20,783,168
20,676,460
9,536,488
10,213,525
8,675,356
10,559,992
9,139,119
8,675,356
7,828,326
7,756,808
300,200
7,510,073
170,851
170,8517,510,073300,2007,756,8087,828,3268,675,3569,139,11910,559,9928,675,35610,213,5259,536,48820,676,46020,783,16818,997,33317,266,97115,194,92612,896,78810,303,4849,941,313



Balance Sheet

Currency in INR. All numbers in thousands.




Cash Flow

Currency in INR. All numbers in thousands.




Income Statement

Currency in INR. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue32,517,200
Cost of Revenue-12,848,700
Gross Profit19,668,50019,668,500
 
Operating Income (+$)
Gross Profit19,668,500
Operating Expense-12,283,300
Operating Income8,391,8007,385,200
 
Operating Expense (+$)
Research Development19,099
Selling General Administrative291,868
Selling And Marketing Expenses1,662,579
Operating Expense12,283,3001,973,546
 
Net Interest Income (+$)
Interest Income698,119
Interest Expense-18,100
Other Finance Cost-698,119
Net Interest Income-18,100
 
Pretax Income (+$)
Operating Income8,391,800
Net Interest Income-18,100
Other Non-Operating Income Expenses0
Income Before Tax (EBT)8,364,0008,419,600
EBIT - interestExpense = 8,373,700
8,394,468
6,124,968
Interest Expense18,100
Earnings Before Interest and Taxes (EBIT)8,391,8008,382,100
Earnings Before Interest and Taxes (EBITDA)9,049,500
 
After tax Income (+$)
Income Before Tax8,364,000
Tax Provision-2,287,600
Net Income From Continuing Ops6,076,4006,076,400
Net Income6,106,868
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations30,500
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses25,132,000
Total Other Income/Expenses Net-27,80018,100
 

Technical Analysis of GlaxoSmithKline Pharmaceuticals Limited
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of GlaxoSmithKline Pharmaceuticals Limited. The general trend of GlaxoSmithKline Pharmaceuticals Limited is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine GlaxoSmithKline Pharmaceuticals Limited's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of GlaxoSmithKline Pharmaceuticals Limited.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 2,165 < 2,268 < 2,524.

The bearish price targets are: 1,842 > 1,782 > 1,727.

Tweet this
GlaxoSmithKline Pharmaceuticals Limited Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of GlaxoSmithKline Pharmaceuticals Limited. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

GlaxoSmithKline Pharmaceuticals Limited Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of GlaxoSmithKline Pharmaceuticals Limited. The current macd is 10.89.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the GlaxoSmithKline Pharmaceuticals Limited price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for GlaxoSmithKline Pharmaceuticals Limited. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the GlaxoSmithKline Pharmaceuticals Limited price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
GlaxoSmithKline Pharmaceuticals Limited Daily Moving Average Convergence/Divergence (MACD) ChartGlaxoSmithKline Pharmaceuticals Limited Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of GlaxoSmithKline Pharmaceuticals Limited. The current adx is 23.95.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy GlaxoSmithKline Pharmaceuticals Limited shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
GlaxoSmithKline Pharmaceuticals Limited Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of GlaxoSmithKline Pharmaceuticals Limited. The current sar is 2,161.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
GlaxoSmithKline Pharmaceuticals Limited Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of GlaxoSmithKline Pharmaceuticals Limited. The current rsi is 44.69. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
GlaxoSmithKline Pharmaceuticals Limited Daily Relative Strength Index (RSI) ChartGlaxoSmithKline Pharmaceuticals Limited Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of GlaxoSmithKline Pharmaceuticals Limited. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the GlaxoSmithKline Pharmaceuticals Limited price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
GlaxoSmithKline Pharmaceuticals Limited Daily Stochastic Oscillator ChartGlaxoSmithKline Pharmaceuticals Limited Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of GlaxoSmithKline Pharmaceuticals Limited. The current cci is -12.03174146.

GlaxoSmithKline Pharmaceuticals Limited Daily Commodity Channel Index (CCI) ChartGlaxoSmithKline Pharmaceuticals Limited Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of GlaxoSmithKline Pharmaceuticals Limited. The current cmo is -19.49777934.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
GlaxoSmithKline Pharmaceuticals Limited Daily Chande Momentum Oscillator (CMO) ChartGlaxoSmithKline Pharmaceuticals Limited Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of GlaxoSmithKline Pharmaceuticals Limited. The current willr is -62.01027617.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that GlaxoSmithKline Pharmaceuticals Limited is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
GlaxoSmithKline Pharmaceuticals Limited Daily Williams %R ChartGlaxoSmithKline Pharmaceuticals Limited Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of GlaxoSmithKline Pharmaceuticals Limited.

GlaxoSmithKline Pharmaceuticals Limited Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of GlaxoSmithKline Pharmaceuticals Limited. The current atr is 64.79.

GlaxoSmithKline Pharmaceuticals Limited Daily Average True Range (ATR) ChartGlaxoSmithKline Pharmaceuticals Limited Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of GlaxoSmithKline Pharmaceuticals Limited. The current obv is 7,112,128.

GlaxoSmithKline Pharmaceuticals Limited Daily On-Balance Volume (OBV) ChartGlaxoSmithKline Pharmaceuticals Limited Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of GlaxoSmithKline Pharmaceuticals Limited. The current mfi is 73.97.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
GlaxoSmithKline Pharmaceuticals Limited Daily Money Flow Index (MFI) ChartGlaxoSmithKline Pharmaceuticals Limited Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for GlaxoSmithKline Pharmaceuticals Limited.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-15BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-01WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-02ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-29MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-30MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-06CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-11BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-27CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-09CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-02STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-05-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-05-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-05-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.

6.3. Candlestick Patterns

GlaxoSmithKline Pharmaceuticals Limited Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of GlaxoSmithKline Pharmaceuticals Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.693
Ma 20Greater thanMa 501,992.870
Ma 50Greater thanMa 1002,011.666
Ma 100Greater thanMa 2002,067.980
OpenGreater thanClose1,975.950
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of GlaxoSmithKline Pharmaceuticals Limited with someone you think should read this too:
  • Are you bullish or bearish on GlaxoSmithKline Pharmaceuticals Limited? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about GlaxoSmithKline Pharmaceuticals Limited? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about GlaxoSmithKline Pharmaceuticals Limited

I send you an email if I find something interesting about GlaxoSmithKline Pharmaceuticals Limited.


Comments

How you think about this?

Leave a comment

Stay informed about GlaxoSmithKline Pharmaceuticals Limited.

Receive notifications about GlaxoSmithKline Pharmaceuticals Limited in your mailbox!